GeneDx Holdings Corp.

GeneDx Holdings Corp. is the operating successor to CM Life Sciences Inc. (Nasdaq: CMLF), a healthcare-focused blank check company that completed its initial public offering in 2021. CM Life Sciences merged with Sema4, a genomic intelligence company, which subsequently acquired the GeneDx genetic testing business from OPKO Health and rebranded under its current name. The company now operates in the clinical genomics sector, providing whole genome sequencing and rare disease diagnostic services. GeneDx Holdings filed an 8-K current report with the SEC on April 16, 2025, reflecting activity at the post-merger operating company level. Sign up on SpacDesk for full filing history, transaction data, and analytics on this and hundreds of other SPAC deals.